Key result
Heart failure in patients with diabetes is an independent disease entity, and SGLT2 inhibitors demonstrate significant protective effects against heart failure in this population.
Why the study?
Heart failure in diabetes is increasingly recognized as an independent entity beyond coronary artery disease, with recent cardiovascular outcome trials demonstrating protective effects of certain anti-diabetic drugs.
This review highlights heart failure as an independent complication of diabetes ('diabetic heart') and emphasizes the guideline-supported role of SGLT2 inhibitors in its prevention and management.
Supports HF screening in diabetes; leaves open dedicated trials for SGLT2 inhibitors in diabetic HF phenotypes.
Heart failure in patients with diabetes has long been considered a consequence of coronary artery disease. However, recent epidemiological evidence from patients with diabetes has shown a significantly increased prevalence of heart failure in patients without significant coronary artery stenosis, suggesting a separate entity involving diabetic complications. Therefore, heart failure in patients with diabetes is now considered as an independent disease entity, 'diabetic heart' . The mechanism of 'diabetic heart' could be coronary artery disease and diabetic cardiomyopathy caused by advanced glycation end products and altered calcium handling, as well as changes to energy metabolism and oxidative stress in the myocardium of patients with diabetes. Recent cardiovascular outcome trials of anti-diabetic medications demonstrated the protective effects of certain drugs against heart failure in patients with and without diabetes. This review summarizes the relationship between diabetes and heart failure, and informs treatment planning for the prevention of heart failure in diabetic patients.
No takes yet. Share an insight, caveat, or question.
Eun‐Jung Rhee (2021) conducted a review in Diabetes and Heart Failure. Anti-diabetic medications was evaluated. Heart failure in patients with diabetes is an independent disease entity, and SGLT2 inhibitors demonstrate significant protective effects against heart failure in this population.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: